Pennsylvania will receive $90,000 of the $39 million that Daiichi Sankyo must pay in damages and penalties to 49 U.S. states, Washington, DC, and the federal government. The National Association of Medicaid Fraud Control and the federal government recently reached the settlement with Daiichi Sankyo after the New Jersey–based pharmaceutical giant was found to have violated federal law in promoting their drugs Azor, Welchol, Tribenzor, and Benicar.
A ...
continue reading...
Daiichi Sankyo Co Ltd, a global pharmaceutical company, is being forced to pay $39 million to the United States government and state Medicaid programs to settle claims that the company paid doctors kickbacks to prescribe its drugs. Reuters reported that the fine was negotiated with the Department of Justice based on a whistleblower case by a former sales representative.
The lawsuit alleged that Daiichi paid doctors kickbacks from 2004 to 2011 to endorse the company’s various ...
continue reading...
A recent post on Medline Plus discusses a study published in an October issue of Circulation. The study found that adequate blood pressure control was more likely with patients who made regular trips to the doctor and had medical insurance.
The researchers reviewed data from 1999 to 2012 on the blood pressure check ups of more than 37,000 Americans. They then controlled for factors like diabetes, body fat, and smoking. Even after accounting for these ...
continue reading...
An article recently published in Pharmacy and Therapeutics Journal has linked the drug olmesartan to drug induced sprue-like enteropathy, a condition that results in issues similar to those caused by celiac disease. Olmesartan is a drug used to treat high blood pressure that is marketed under the brand names Benicar, Benicar HCT, Azor, and Tribenzor, as ...
